Advances in ultrasensitive assays now allow reliable quantification of key markers such as p-tau181, p-tau217, NfL, and GFAP in blood, with good predictive performance for neurodegenerative diseases causing dementia (Grande et al., 2025). This evidence concerns the gene GFAP and dementia.